Industry · STRICT crypto policy
QNSP for Healthcare & Life Sciences
HIPAA + GDPR + PDPA-aligned PQC for hospitals, pharma research, clinical trials, and PHI exchanges.
PHI-safe encrypted storage, PQC-authenticated research data exchanges, and de-identification controls for hospitals, pharma R&D, clinical trial networks, and health information exchanges. Meets HIPAA Security Rule, GDPR, and PDPA Singapore through data-layer policying.
Threat model
What we're defending against
The HNDL, regulatory, and operational threats specific to this vertical.
PHI with lifetime confidentiality requirement
Genomic, psychiatric, reproductive-health, and HIV records retain confidentiality value across a patient's lifetime — and often their children's. Multi-decade HNDL exposure is real.
Cross-institution research data exchange
Clinical trials and rare-disease consortia move de-identified PHI across borders and institutions. PQC signatures on every exchange let receivers verify authenticity without trusting the transport.
Insider-attack on bulk PHI
Tenant isolation + per-record encryption + per-access audit means an exfiltrated database dump is plaintext-empty; the attacker must also breach the per-key access boundary.
Compliance mapping
Frameworks this vertical operates under
QNSP supports continuous evaluation for 7 live frameworks; other named frameworks are architecturally supported with evidence available on request.
| Framework | How QNSP maps |
|---|---|
| HIPAA Security Rule ↗ | §164.312(a)(2)(iv) Encryption — addressable safeguards met via QNSP vault + SSE-X with ML-KEM-768 wrapping AES-256-GCM data keys. |
| GDPR ↗ | Article 32 (Security of processing) — pseudonymisation, encryption, integrity, and resilience via QNSP de-identification + audit chain. |
| PDPA (Singapore) ↗ | Protection Obligation (§24) and Notification Obligation (§26) — QNSP vault encryption-at-rest and tamper-evident breach evidence. |
| ISO/IEC 27001:2022 ↗ | A.5.34 (Privacy and protection of PII) and A.8.24 (Use of cryptography) — QNSP crypto-policy enforcement. |
| 21 CFR Part 11 (FDA) | Electronic records and signatures for clinical trials — ML-DSA-65 signatures on every record meet the authenticity and non-repudiation requirements. |
QNSP architecture
Capabilities mapped to this vertical
How QNSP services compose to meet this vertical's needs.
Per-patient encryption keys; vault retention locks meet HIPAA 6-year audit-log requirements
Search across encrypted clinical records without decrypting bulk data — supports cohort discovery
Per-hospital / per-trial-arm isolation prevents cross-tenant PHI bleed
Every PHI access produces an immutable audit entry — meets §164.312(b) audit-controls requirement
Outcomes
What deploying QNSP for this vertical delivers
- ✓HIPAA Security Rule addressable safeguards met without bespoke encryption infrastructure
- ✓Per-record encryption — bulk database exfiltration is plaintext-empty
- ✓PQC-signed cross-institution exchanges with verifiable provenance
- ✓Continuous compliance evidence for HIPAA, GDPR, PDPA — not annual snapshots
For your engineers
Build patterns that map to this vertical
When you've evaluated the platform, hand these references to your engineering team.
Next step